In 2023, Kaken Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Kaken Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 11,069a | 11,968a | 12,047a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 10,339a | 9,699a | 9,823a | |
Total Scope 3 | N/A | 125,719a | 126,563a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 20.2017a | 19.2065a | 17.7229a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Kaken Pharmaceutical amounted to 21,408 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Kaken Pharmaceutical decreased by 1.2%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2023, the total Scope 1 emissions of Kaken Pharmaceutical were 11,069 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Kaken Pharmaceutical's Scope 1 emissions have decreased by 14.33%, reflecting a declining long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), Kaken Pharmaceutical's Scope 1 emissions decreased by 7.51%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2023, Kaken Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 10,339 tCO₂e without specifying the calculation method.a
Since 2019, Kaken Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Kaken Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2022), Kaken Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Kaken Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2023, Kaken Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Kaken Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 11,069 tCO₂e and total revenues of USD 548 millions. This translates into an emissions intensity of 20.2 tCO₂e per millions USD.a
In 2023, Kaken Pharmaceutical reported a Scope 1 emissions intensity of 20.2 tCO₂e per millions USD. Compared to the peer group median of 12.12, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Kaken Pharmaceutical ranked 18 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Kaken Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a